A step forwarded on the in vitro and in vivo validation of rifabutin-loaded liposomes for the management of highly virulent MRSA infections DOI Creative Commons
Mariana Coelho, Jacinta O. Pinho, Sandra N. Pinto

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 348 - 361

Published: Feb. 8, 2025

Staphylococcus aureus (S. aureus) infections, especially methicillin resistant (MRSA), constitute an alarming public health issue due to its association with high mortality, morbidity, and hospitalization costs. The increasing antibiotic resistance biofilm-associated infections of MRSA prompted the discovery novel more effective therapeutic strategies. Our team has been working on alternative therapies against S. infections. For this, we have repurposing existing antibacterial drug, rifabutin (RFB), through a nanotechnological platform, liposomes, aiming promote preferential targeting infected sites maximizing potential effect. RFB formulations commercial strain (MRSA ATCC®-33592), either in planktonic or biofilm forms, was assessed. displayed higher effects towards than vancomycin (VCM), gold standard treatment MBIC50 values 103 > 800 μg/ml, respectively. Moreover, antimicrobial effect RFB-loaded liposomes demonstrated be lipid composition-dependent based MIC50 values, which also confirmed by confocal laser scanning microscopy. These studies supported that for positively charged electrostatic interaction at surface occurs without internalization. On other hand, neutral charge internalization within observed. this liposomal formulation stable human plasma, as 83 % still associated 24 h after incubation 37 °C. proof concept assessed systemic murine models infection. Therapeutic survival rates were evaluated animals induced treated free forms compared negative positive controls. lower infection model, 100 achieved all groups under study. However, model only group incorporated attained. In terms bacterial burden, exhibited levels when VCM, even using dose: 20 vs 40 mg/kg body weight, Overall, constitutes strategy being potentiated nanoplatform.

Language: Английский

Exploring Innovative Antibacterial Properties of Porous ALT (Al2O3/TiO2) Composite DOI
Muhammad Yousaf,

Rana Mustansar Munir,

Tahir Iqbal

et al.

Materials Chemistry and Physics, Journal Year: 2024, Volume and Issue: 325, P. 129736 - 129736

Published: July 16, 2024

Language: Английский

Citations

4
Advanced Nanotechnological Approaches for Biofilm Prevention and Control DOI Creative Commons
María Pía Ferraz

Applied Sciences, Journal Year: 2024, Volume and Issue: 14(18), P. 8137 - 8137

Published: Sept. 10, 2024

Biofilm-associated infections present a significant challenge in modern medicine, primarily due to their resilience and resistance conventional treatments. These occur when bacteria form biofilms, protective layers formed by bacterial communities, which are notoriously resistant traditional antibiotics on surfaces such as medical implants biological surfaces, making eradication with standard difficult. This leads persistent infections, imposing substantial economic burden healthcare systems. The urgency find alternative treatments is critical current methods insufficient costly. Innovative approaches, nanotechnology-based therapies, offer promising alternatives targeting biofilms more effectively reducing the need for invasive procedures. Nanocarriers hold promise fight against biofilm-associated infections. can penetrate than treatments, delivering higher concentrations of or other antimicrobial agents precisely where they needed. targeted approach not only enhances efficacy but also minimizes potential side effects. development nanocarrier-based therapies crucial overcoming limitations ultimately improving patient outcomes In this review, systems, characteristics, limitations, benefits explored address biofilms-related Additionally, biofilm evaluation models tests necessary preclinical validation these nanosystems facilitate clinical application addressed.

Language: Английский

Citations

4
Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance DOI

Fahaad Alenazi,

Mohd Shahid Khan

Acta Diabetologica, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 6, 2025

Language: Английский

Citations

0
Superhydrophilic on air/superoleophobic underwater membranes prepared by electrochemical formation of CuI for water–oil separation: Preparation, performance, water corrosion and biofouling studies DOI
Ivana K. Levy, Antonela Cánneva, R. Martı́n Negri

et al.

Materials Chemistry and Physics, Journal Year: 2025, Volume and Issue: unknown, P. 130425 - 130425

Published: Jan. 1, 2025

Language: Английский

Citations

0
A step forwarded on the in vitro and in vivo validation of rifabutin-loaded liposomes for the management of highly virulent MRSA infections DOI Creative Commons
Mariana Coelho, Jacinta O. Pinho, Sandra N. Pinto

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 348 - 361

Published: Feb. 8, 2025

Staphylococcus aureus (S. aureus) infections, especially methicillin resistant (MRSA), constitute an alarming public health issue due to its association with high mortality, morbidity, and hospitalization costs. The increasing antibiotic resistance biofilm-associated infections of MRSA prompted the discovery novel more effective therapeutic strategies. Our team has been working on alternative therapies against S. infections. For this, we have repurposing existing antibacterial drug, rifabutin (RFB), through a nanotechnological platform, liposomes, aiming promote preferential targeting infected sites maximizing potential effect. RFB formulations commercial strain (MRSA ATCC®-33592), either in planktonic or biofilm forms, was assessed. displayed higher effects towards than vancomycin (VCM), gold standard treatment MBIC50 values 103 > 800 μg/ml, respectively. Moreover, antimicrobial effect RFB-loaded liposomes demonstrated be lipid composition-dependent based MIC50 values, which also confirmed by confocal laser scanning microscopy. These studies supported that for positively charged electrostatic interaction at surface occurs without internalization. On other hand, neutral charge internalization within observed. this liposomal formulation stable human plasma, as 83 % still associated 24 h after incubation 37 °C. proof concept assessed systemic murine models infection. Therapeutic survival rates were evaluated animals induced treated free forms compared negative positive controls. lower infection model, 100 achieved all groups under study. However, model only group incorporated attained. In terms bacterial burden, exhibited levels when VCM, even using dose: 20 vs 40 mg/kg body weight, Overall, constitutes strategy being potentiated nanoplatform.

Language: Английский

Citations

0